"In trying to localize and focalize the treatment on just the lesion of prostate cancer, HIFU was incredibly powerful in the sense that it really allowed you to do that with great precision," said Jennifer Linehan, MD.
As part of the Urology Times' 50th Anniversary Innovation Celebration, Jennifer Linehan, MD, discusses how high-intensity focused ultrasound (HIFU) revolutionized the way urologists treat localized prostate cancer. This techology, she emphasizes, creates another safe and effective minimally-invasive therapy for this population of patients. Linehan is an associate professor of urology and urologic oncology at the John Wayne Cancer Institute in Santa Monica, California.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.